ALSA Ventures is a life science venture capital investor, focused on early stage novel therapeutics. With a strong operations background in drug development, our team seeks to bring together outstanding entrepreneurs and world class academic researchers to help bring promising new treatments to market. We invest across a wide spectrum of therapeutic areas, targeting high unmet need with impactful outcomes for patients and society at large.
Location: United Kingdom, England, Westminster
Employees: 1-10
Founded date: 2019
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A
Portfolio 7
| Date | Name | Website | Total Raised | Location |
| 12.06.2025 | ReproNovo | repronovo.com | $65M | - |
| 27.10.2023 | Axovia The... | axoviatherapeutics.com | - | United Kin... |
| 21.07.2023 | Vantage Bi... | vantage-biosciences.com | - | - |
| - | Montis Bio... | montisbiosciences.com | $9.14M | Belgium, F... |
| - | Epsilogen ... | epsilogen.com | $61.08M | - |
| - | Oxford Bio... | oxfordbiotherapeutics.com | $20M | United Kin... |
| - | Promatix | pro-matix.com | - | - |
Persons 10
| Date | First Name | Last Name | Title | Location | |||
| - | Andre | Badalyan | Analyst | linkedin.c... | - | - | - |
| - | Alek | Safarian | CEO | linkedin.c... | - | - | - |
| - | Lorna | Collings | CFO | linkedin.c... | - | - | - |
| - | Dr | Graeme Mar... | Consultant | linkedin.c... | - | - | - |
| - | Laura | Higgins | Accounts A... | - | - | - | |
| - | Dr | Robert Bal... | - | linkedin.c... | - | - | - |
| - | Katie | Sunnucks | - | linkedin.c... | - | - | - |
| - | Diana | Smith | Executive ... | - | - | - | |
| - | Julia | Jones | - | linkedin.c... | - | - | - |
| - | Dr | Bruce Gold... | - | - | - | - |
News 43
| Date | Title | Description |
| 11.07.2024 | Epsilogen announces CTA approval for Phase Ib trial of MOv18 IgE in platinum-resistant ovarian cancer | Phase Ib study expected to initiate in H2 2024 Previously reported Phase I results showedMOv18 IgE to be safe and well tolerated, with evidence of anti-tumour activity LONDON, 8 July 2024 – Epsilogen, a global leader in the development of ... |
| 02.05.2024 | Epsilogen appoints Ashley Nagle as Chief Business Officer and Peter Finan as Non-Executive Chairman as part of broader company expansion | LONDON, 3 April 2024 – Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces the appointments of Ashley Nagle as Chief Business Officer(CBO) and Peter Finan as Non-Executive Chai... |
| 01.05.2024 | Alek Safarian shares his opinions on the current funding environment for biotech, and introduces ALSA Ventures and its investment philosophy. | ALSA Ventures CEO Alek Safarian recently sat down with BiotechTV to share his views on the current biotech venture capital funding environment in UK and Europe, and where the industry is heading. |
| 24.10.2023 | Oxford BioTherapeutics announces that partner Boehringer Ingelheim dosed the first patient in a Phase 2 trial investigating BI 764532 (OBT620) for the treatment of small cell lung cancer (SCLC) and ot... | BI 764532 was discovered using OBT’s proprietary OGAP® platform, the world's largest, cancer specific, membrane protein library used to identify novel, high specific antigens for cancer targets |
| 03.10.2023 | Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Treatment of Extensive Stage Small Cell Lung Cancer and Extrapulmonary Neur... | · BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 protein |
| 18.09.2023 | ALSA Ventures announces the acquisition of Axovia Therapeutics Inc and the launch of a new portfolio company Axovia Therapeutics Ltd. | · Developing the first gene therapy to treat diseases caused by cilia dysfunction |
| 18.09.2023 | ALSA Ventures announces the acquisition of Axovia Therapeutics Inc and the launch of a new portfolio company Axovia Therapeutics Ltd | ·      Developing the first gene therapy to treat diseases caused by cilia dysfunction ·      AXV101 targets retinal dystrophy for Bardet-Biedl Syndrome (BBS) patients ·      FDA Orphan Drug Designation and Rare Paediat... |
| 31.07.2023 | Epsilogen announces successful completion of first ever clinical trial of an IgE antibody; phase I data for MOv18 IgE demonstrates potential of IgE therapy in cancer | Final results of phase I study of MOv18 IgE in ovarian cancer published in Nature Communications MOv18 IgE found to be safe and well tolerated with evidence of anti-tumour activity observed |
| 19.07.2023 | ALSA Ventures launches Vantage Biosciences to treat Diabetic Eye Disease | · Diabetic eye diseases are the leading cause of blindness in the working age population |
| 19.10.2022 | Promatix and Jasmin Fisher Lab at University College London Accelerate Hunt for Oncology Therapeutics with New Algorithms for CipherPro. | London, 19 October 2022 – Promatix, a London-based oncology drug discovery and development company that uses multi-omics to identify novel therapeutics, today announced a collaboration with the laboratory of Professor Jasmin Fisher to devel... |
Show more
Mentions in press and media 7
| Date | Title | Description |
| 03.03.2026 | HiRO Leads Cross‑Border Dialogue at JPM, Offering Insights for Biotechs Seeking Asian Investment | SOMERSET, N.J., March 3, 2026 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a global contract research organization specializing in strategic planning for clinical development and cross‑border clinical trial solutions and... |
| 22.05.2025 | ReproNovo's $65 Million Leap: A New Dawn for Reproductive Health | In a world where fertility rates are slipping like sand through fingers, ReproNovo emerges as a beacon of hope. This Swiss HealthTech startup, founded in 2021, has just secured $65 million in Series A financing. The funding round, led by Je... |
| 21.05.2025 | Swiss HealthTech company ReproNovo raises €57 million to tackle declining fertility rates | Lausanne-based HealthTech startup ReproNovo, a company innovating treatments for reproductive medicine and women’s health, has secured a €57 million Series A financing round. The round was led by Jeito Capital, AXA IM and M Ventures, alongs... |
| 21.05.2025 | ReproNovo raises USD65 million to advance Phase II clinical trials | ReproNovo, founded in 2021, is developing novel approaches to address critical gaps in reproductive medicine and women’s health, including male and female infertility as well as uterine health. The company, led by a team with expertise in ... |
| 10.09.2024 | Epsilogen Secures £12.5 Million to Propel Cancer Treatment Innovations | Epsilogen, a pioneering force in the realm of immunoglobulin E (IgE) antibodies, has successfully raised £12.5 million in a Series B funding round. This brings the total Series B financing to an impressive £43.25 million. The funds will be ... |
| 09.09.2024 | Epsilogen: Immunoglobulin Development Company Raises £12.5 Million (Series B) | Epsilogen – a leader in the development of immunoglobulin E (IgE) antibodies to treat cancer – announced today the completion of a £12.5 million Series B expansion financing, bringing the Series B total to £43.25 million. The funding will a... |
| 22.03.2022 | BioNeex and ALSA Ventures Partner to Provide Biotech Firms a New Way to Drug Candidate Out-Licensing and Acquiring Investment | NEW YORK (PRWEB) March 22, 2022 BioNeex (http://www.bioneex.com), the biopharma industry’s first research and development (R&D) open exchange platform, announced today it is partnering with ALSA Ventures to help preclinical and early cl... |